Atropine; pralidoxime chloride - Generic Drug Details

What are the generic drug sources for atropine; pralidoxime chloride and what is the scope of patent protection?

Atropine; pralidoxime chloride is the generic ingredient in two branded drugs marketed by Us Army and MMT, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

Two suppliers are listed for this compound.

Summary for atropine; pralidoxime chloride

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	2
Clinical Trials:	1
DailyMed Link:	atropine; pralidoxime chloride at DailyMed

Recent Clinical Trials for atropine; pralidoxime chloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sir Salimullah Medical College Mitford Hospital	Phase 2

See all atropine; pralidoxime chloride clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for atropine; pralidoxime chloride

A03BA	Belladonna alkaloids, tertiary amines
A03B	BELLADONNA AND DERIVATIVES, PLAIN
A03	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
A	Alimentary tract and metabolism

S01FA	Anticholinergics
S01F	MYDRIATICS AND CYCLOPLEGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

V03AB	Antidotes
V03A	ALL OTHER THERAPEUTIC PRODUCTS
V03	ALL OTHER THERAPEUTIC PRODUCTS
V	Various

US Patents and Regulatory Information for atropine; pralidoxime chloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mmt	DUODOTE	atropine; pralidoxime chloride	INJECTABLE;INTRAMUSCULAR	021983-001	Sep 28, 2006		RX	Yes	Yes
Us Army	ATNAA	atropine; pralidoxime chloride	INJECTABLE;INTRAMUSCULAR	021175-001	Jan 17, 2002		DISCN	No	No

Expired US Patents for atropine; pralidoxime chloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Mmt	DUODOTE	atropine; pralidoxime chloride	INJECTABLE;INTRAMUSCULAR	021983-001	Sep 28, 2006	5,092,843

Atropine and Pralidoxime Chloride Market Dynamics, Patent Status, and Financial Trajectory

Last updated: September 3, 2026

Atropine and pralidoxime chloride are emergency antidotes for organophosphate nerve-agent and pesticide poisoning. The U.S. market is procurement-driven rather than prescription-driven. Demand is concentrated in the Department of Defense, Department of Homeland Security, public-health agencies, emergency responders, and national stockpiles.

The principal combination products are DuoDote and ATNAA, both supplied as intramuscular autoinjectors containing atropine and pralidoxime chloride. Product-level revenue is not separately disclosed by the manufacturers. Commercial performance depends on government contracts, stockpile replacement cycles, manufacturing capacity, and geopolitical risk rather than routine patient volume.

What products contain atropine and pralidoxime chloride?

The main U.S. combination products use the same pharmacologic components but differ in device design, labeling, and procurement history.

Product	Active ingredients	Delivery	Primary users	U.S. regulatory status
DuoDote	Atropine 2.1 mg and pralidoxime chloride 600 mg	Single-use IM autoinjector	Military, emergency responders, government stockpiles	FDA-approved NDA product
ATNAA	Atropine 2.1 mg and pralidoxime chloride 600 mg	Single-use IM autoinjector	Military and federal procurement channels	FDA-approved NDA product
Separate atropine injection plus pralidoxime injection	Atropine sulfate and pralidoxime chloride	Manual injection or separate devices	Hospitals, military, toxicology services	Multiple approved products and formulations

DuoDote and ATNAA are designed for rapid administration when exposure to nerve agents or organophosphate pesticides is suspected. Atropine counters muscarinic cholinergic effects. Pralidoxime reactivates acetylcholinesterase before enzyme aging limits the benefit of oxime therapy. Product labels require repeated dosing when symptoms persist or recur.[1][2]

How do DuoDote and ATNAA compare?

DuoDote has historically been associated with military and emergency-response procurement. ATNAA entered the U.S. market later and provided an alternative autoinjector product for federal and defense buyers.

The products compete on:

• Unit price and total contract economics
• Autoinjector reliability
• Shelf life and replacement requirements
• Manufacturing capacity
• Human-factors performance
• Government qualification and deployment history
• Ability to supply large orders quickly

The active-ingredient differentiation is limited. The principal competitive variables are device integration, production scale, regulatory compliance, and contract access.

What is the FDA regulatory status of atropine and pralidoxime chloride?

DuoDote and ATNAA are FDA-approved prescription products. Their approved use is emergency treatment of poisoning by organophosphorus nerve agents and organophosphorus insecticides.[1][2]

The regulatory structure differs from ordinary commercial pharmaceuticals:

1. The products are approved drugs.
2. The principal customers often are government agencies rather than retail pharmacies.
3. Demand can arise from preparedness programs without corresponding increases in diagnosed poisoning cases.
4. Procurement specifications may require an autoinjector rather than separate ampules or vials.
5. Manufacturing changes can affect contract eligibility, product availability, and stockpile replenishment.

The combination product is not a biologic. Biosimilar approval pathways therefore do not apply. A competing product would generally require an abbreviated new drug application if it can demonstrate pharmaceutical equivalence and bioequivalence, or a 505(b)(2) application if it relies partly on published data while introducing differences in formulation, device, or clinical use.

What patents protect atropine and pralidoxime chloride products?

The active ingredients are long-established and are not protected by composition-of-matter patents in the U.S. The commercial patent question concerns the autoinjector, combination formulation, manufacturing process, and use claims.

What is the Orange Book status of DuoDote and ATNAA?

The FDA Orange Book is the controlling source for listed patents and regulatory exclusivity. Publicly available product information does not indicate a major, currently active Orange Book patent estate that creates a long-duration exclusivity barrier for the active ingredients.[3]

The relevant IP categories are:

IP category	Commercial relevance
Atropine composition claims	Low; active ingredient is old
Pralidoxime composition claims	Low; active ingredient is old
Combination formulation claims	Potentially relevant but narrow
Autoinjector configuration claims	Potentially relevant to device competitors
Dose-delivery and safety-lock claims	May affect substitutability
Manufacturing-process claims	Can create practical supply barriers
Method-of-use claims	May cover particular emergency-treatment protocols
Trade secrets and know-how	Important for device assembly and quality control

The absence of a significant active-ingredient patent barrier does not mean immediate generic substitution. A rival manufacturer must still establish product quality, dose accuracy, device reliability, stability, packaging performance, and user handling.

When does atropine and pralidoxime chloride lose exclusivity?

The active ingredients have already lost conventional small-molecule exclusivity. The remaining protection is product-specific and may arise from:

• Device patents
• Combination-product patents
• Regulatory exclusivity
• Confidential manufacturing processes
• Government qualification requirements
• Contractual barriers
• Manufacturing capacity constraints

FDA approval dates alone do not establish the end of all commercial protection. Patent expiry must be checked at the individual listed-patent level in the current Orange Book and in relevant patent records. For this market, regulatory and procurement barriers are more material than new-molecule exclusivity.

Are there Paragraph IV challenges to DuoDote or ATNAA?

No major, publicly established Paragraph IV litigation campaign has defined the U.S. market for DuoDote or ATNAA through 2024. That outcome is commercially logical because the market is small, government-centered, and operationally complex.

A Paragraph IV challenger would need to assess:

• Whether a reference product has listed patents
• Whether the proposed product is therapeutically equivalent
• Whether the autoinjector can qualify as the same dosage form
• Whether device differences require a 505(b)(2) pathway
• Whether expected government volume supports litigation costs
• Whether the innovator could defend device or process claims

The absence of high-profile Paragraph IV litigation reduces legal uncertainty but does not eliminate competitive entry risk. A challenger could pursue a non-infringing 505(b)(2) strategy or compete for government contracts without directly relying on an ANDA substitution model.

What generic entry risks exist for atropine and pralidoxime chloride?

Generic entry is technically feasible but commercially selective.

Generic autoinjector risk

A competing autoinjector must match or adequately justify differences in:

• Atropine and pralidoxime dose
• Injection volume
• Needle depth
• Activation force
• Injection time
• Temperature performance
• Shelf life
• Container-closure integrity
• Accidental activation protection
• Human-factors usability

Autoinjector products are combination products. The drug formulation may be straightforward, but the device and drug-device interface can create development and review risk.

Separate-injection risk

Separate atropine and pralidoxime products may be easier to manufacture and approve but less attractive for emergency deployment. They require more handling and can impose a higher operational burden on users. They may remain competitive in hospitals and poison-control settings while being less suitable for military kits and first-responder stockpiles.

Generic launch scenarios

Scenario	Market effect	Probability driver
New autoinjector supplier wins a federal contract	Price pressure and share migration	FDA approval, qualification, production capacity
Separate injectable supplier expands hospital use	Limited substitution of combination autoinjectors	Hospital protocols and inventory economics
Government increases stockpile purchases	Higher volumes for qualified suppliers	Geopolitical or preparedness events
Government reduces inventories	Lower revenue and excess manufacturing capacity	Budget and policy decisions
Manufacturing disruption	Temporary supply tightening	Facility, component, or quality issues

What patent litigation affects atropine and pralidoxime chloride?

There is no widely reported, market-defining patent litigation comparable to litigation in major chronic-care drug categories. The principal legal risks are more likely to involve:

• Device infringement
• Contract disputes
• Government procurement protests
• Manufacturing quality issues
• Supply agreements
• Product liability
• Regulatory enforcement
• Substitution and therapeutic-equivalence disputes

Settlement agreements are not a central publicly visible feature of this market. Government supply contracts may contain confidential commercial terms, including pricing, delivery obligations, option periods, and termination rights.

Which companies are challenging or competing with the leading products?

Competition comes from product manufacturers, contract manufacturers, and suppliers of separate injectable antidotes. The commercially relevant competitive set includes:

• Meridian Medical Technologies, associated with DuoDote and ATNAA supply
• Manufacturers of atropine sulfate injection
• Manufacturers of pralidoxime chloride injection
• Potential 505(b)(2) developers of combination autoinjectors
• Government-qualified contract manufacturers
• International suppliers serving military and civil-defense markets

The market is not comparable to a broad retail generic category. A company can obtain FDA approval and still fail to achieve meaningful sales if it lacks validated autoinjector production, federal contracting access, or adequate inventory capacity.

How large is the atropine and pralidoxime chloride market?

A reliable global market figure is not available from public manufacturer reporting because DuoDote, ATNAA, and related products are not reported as standalone revenue lines.

The addressable market has four segments:

1. U.S. military procurement
2. Federal and state emergency stockpiles
3. First-responder and hazardous-materials programs
4. Hospital and occupational-poisoning treatment

Military and government purchases likely account for the largest share of combination-autoinjector demand. Hospital demand is more fragmented and tends to favor separate injectable products, depending on local treatment protocols.

Revenue is therefore lumpy. A supplier can experience a sharp increase in annual sales when a large procurement contract is awarded, followed by lower revenue during periods when agencies consume existing stock or defer replacement.

What drives the financial trajectory of the market?

Government contract cycles

The main financial driver is the replacement cycle for stockpiled antidotes. Autoinjectors have finite shelf lives, and agencies must replace expiring inventory even when actual poisoning incidents remain low.

Geopolitical preparedness

Chemical-threat concerns, military deployments, terrorism alerts, and civil-defense programs can increase procurement. These effects are difficult to forecast using conventional prescription-volume models.

Manufacturing concentration

The market benefits incumbent suppliers with validated production lines, specialized filling and assembly capabilities, and experience with federal quality requirements. Manufacturing concentration can support pricing but also creates supply continuity risk.

Product mix

Combination autoinjectors generally have higher unit value than separate vials or ampules because the product includes an integrated delivery system. The premium reflects device components, assembly, testing, packaging, and deployment requirements.

Contract pricing

Government buyers can exert strong price pressure because purchases are concentrated and competitive bidding is common. A supplier may accept lower unit margins to secure a multiyear contract, improve plant utilization, or maintain strategic qualification.

How strong is the patent estate for atropine and pralidoxime chloride?

The patent estate is weak for the active ingredients and potentially moderate for specialized delivery systems.

Estate component	Strength	Reason
Atropine molecule	Very low	Long-established generic drug
Pralidoxime molecule	Very low	Long-established generic drug
Combination composition	Low to moderate	Narrow formulation and dose claims
Autoinjector design	Moderate	Device-specific claims may remain enforceable
Manufacturing know-how	Moderate to high	Difficult to replicate quickly
Regulatory and procurement position	High practical value	Qualification and supply history matter
Brand recognition	Limited outside government channels	Buyers prioritize performance and supply

The commercial moat is operational rather than pharmaceutical. A new entrant may face greater difficulty reproducing a qualified supply chain than avoiding active-ingredient patent claims.

What geographic markets matter?

The United States is the most important market because of military procurement and federal preparedness programs. Other relevant markets include countries with:

• Military chemical-defense programs
• Large pesticide-exposure burdens
• National emergency stockpiles
• Civil-defense systems
• Centralized government purchasing

International expansion requires country-specific registration, packaging, language, pharmacovigilance, and procurement approvals. U.S. FDA approval does not automatically confer foreign market access.

Key Takeaways

• Atropine and pralidoxime chloride are mature active ingredients with no meaningful composition-of-matter exclusivity.
• DuoDote and ATNAA are the principal U.S. combination autoinjector products.
• The market is driven by government procurement, stockpile replacement, and geopolitical preparedness.
• Product-level revenue is not separately disclosed, so financial analysis must rely on contract activity and supplier exposure.
• Biosimilar risk does not apply because these are small-molecule drug products.
• Paragraph IV litigation has not materially shaped the market through 2024.
• Autoinjector engineering, manufacturing validation, shelf life, and procurement qualification are more important barriers than active-ingredient patents.
• Generic or 505(b)(2) entry is feasible but may be commercially unattractive without federal contracts.
• Revenue is likely to remain episodic, with sharp procurement-driven peaks and replacement-cycle declines.

FAQs

Is atropine and pralidoxime chloride available over the counter?

No. These products are prescription emergency antidotes and are primarily supplied to military, government, emergency-response, and institutional customers.

Is pralidoxime chloride the same as 2-PAM?

Yes. Pralidoxime chloride is commonly referred to as 2-PAM, short for pralidoxime.

Can a hospital substitute separate atropine and pralidoxime for DuoDote?

Clinical substitution depends on the product label, institutional protocol, dose requirements, and emergency-treatment circumstances. Separate products do not provide the same integrated autoinjector delivery system.

Does ATNAA have orphan-drug exclusivity?

The commercial product’s protection is not primarily based on orphan-drug exclusivity. Its market position depends on FDA approval, device performance, manufacturing capability, and government procurement.

What is the largest risk to investors evaluating this market?

The largest risk is revenue concentration in government contracts. A supplier can have strong technical qualifications but experience declining sales if a procurement cycle is delayed, a contract is lost, or stockpile replacement demand falls.

References

1. U.S. Food and Drug Administration. (n.d.). DuoDote atropine and pralidoxime chloride injection prescribing information. FDA.
2. U.S. Food and Drug Administration. (n.d.). ATNAA atropine and pralidoxime chloride injection prescribing information. FDA.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Content and format. FDA.
5. U.S. Department of Defense. (2024). Chemical and biological defense medical countermeasure procurement programs. U.S. Department of Defense.
6. U.S. Department of Health and Human Services. (2024). Strategic National Stockpile and medical countermeasure preparedness. Administration for Strategic Preparedness and Response.